Chemosensitivity of a novel Akt inhibitor, MK2206, in gastric cancer cell lines

被引：0
|
作者：
Kim, Hyosong [1 ]
Kim, Tae Soo [1 ]
Kwan, Bo Ram [1 ]
Kim, Jeong Min [1 ]
Park, Chan Hee Park [1 ]
Jeung, Hei-Cheul [1 ]
Ahn, Joong-Bae [1 ]
Shin, Sang-Joon [1 ]
Chung, Hyun Cheol [1 ]
Rha, Sun Young [1 ]
机构：
[1] Yonsei Canc Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-1986
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1986
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Effect of a Novel Akt Inhibitor MK-2206 on Proliferation and Chemosensitivity of Gastric Cancer
    Jin, Piaopiao
    Sun, Leimin
    GASTROENTEROLOGY, 2015, 148 (04) : S948 - S949
  • [2] Preclinical evaluation of the AKT inhibitor MK2206 in nasopharyngeal carcinoma cell lines
    Ma, Brigette B.
    Lui, Vivian W. Y.
    Hui, Connie
    Lau, Cecilia
    Ng, Margaret
    Tsao, S. W.
    Hui, Edwin P.
    Wong, C. H.
    Yan, Li
    Chan, Anthony T. C.
    CANCER RESEARCH, 2012, 72
  • [3] MK2206, an AKT-inhibitor, sensitizes osteosarcoma cell lines to topoisomerase II inhibitors
    Galembikova, A.
    Bikinieva, F.
    Boichuk, S.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 : 142 - 142
  • [4] Preclinical modeling of the AKT inhibitor MK2206 and topotecan in small cell lung cancer (SCLC)
    Holland, William S.
    Chinn, Danielle C.
    Lara, Primo
    Gandara, David R.
    Mack, Philip C.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines
    Almhanna, Khaldoun
    Cubitt, Christopher L.
    Zhang, Shumin
    Kazim, Sabiha
    Husain, Kazim
    Sullivan, Daniel
    Sebti, Said
    Malafa, Mokenge
    CANCER BIOLOGY & THERAPY, 2013, 14 (10) : 932 - 936
  • [6] Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer
    Stottrup, Casey
    Tsang, Tiffany
    Chin, Y. Rebecca
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1964 - 1974
  • [7] MK2206, a selective AKT inhibitor, modulates ovarian cancer cell line sensitivity to carboplatin plus paclitaxel
    Zgheib, N. Bou
    Marchion, D.
    Xiong, Y.
    Stickles, X.
    Judson, P.
    Hakam, A.
    Bosquet, J. Gonzalez
    Wenham, R.
    Apte, S.
    Lancaster, J.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S140 - S140
  • [8] Significant in-vitro anti-myeloma activity of a novel Akt inhibitor MK2206
    Ramakrishnan, Vijay
    Haug, Jessica
    Kimlinger, Teresa
    Hailing, Timothy
    Wellik, Linda
    Rajkumar, S. Vincent
    Kumar, Shaji
    CANCER RESEARCH, 2010, 70
  • [9] MK2206, an orally active allosteric AKT inhibitor, reverses progestin resistance in endometrial cancer
    Pant, A.
    Lee, I.
    Lurain, J.
    Schink, J.
    Kim, J.
    GYNECOLOGIC ONCOLOGY, 2011, 123 (02) : 438 - 439
  • [10] Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
    Oki, Yasuhiro
    Fanale, Michelle
    Romaguera, Jorge
    Fayad, Luis
    Fowler, Nathan
    Copeland, Amanda
    Samaniego, Felipe
    Kwak, Larry W.
    Neelapu, Sattva
    Wang, Michael
    Feng, Lei
    Younes, Anas
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (04) : 463 - 470
12345